Emergent BioSolutions (EBS) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.99 -0.13%
Revenue Growth %: +32.0%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +32.0%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $1.57, $0.16 worse than the analyst estimate of $1.73. Revenue for the quarter came in at $360.4 million versus the consensus estimate of $357.41 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
- Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
